CFTR modulators and biologics have had a significant impact on the treatment of cystic fibrosis and severe asthma in recent years. Despite all the benefits that these active substances bring, some patients can also experience significant side effects. Some extrapulmonary consequences still receive too little attention in practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Cutaneous Crohn's disease
Effective alternative to TNF inhibitors
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Benralizumab in a patient with asthma and EGPA
When the biologic has a counterproductive effect
- Brain atrophy and MS
Brain atrophy correlates with disability progression in MS
- Diabetes mellitus
Treatment of comorbidities in older people
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Pulmonary sarcoidosis
Prednisone vs. MTX: a draw after 24 weeks
- Friedreich's ataxia